*Listed in no particular order
Xiangxue Life Sciences (XLifeSc) is a biopharmaceutical company focused on TCR-based therapies for cancer. Our main proprietary technological platforms are composed of: (1) High Affinity T Cell Activation Core (HATac) ; (2) TCR Affinity Enhancing Specific T Cell Therapy (TAEST) . The two platforms have been fully developed to the clinic-ready stage.
Stemirna Therapeutics was founded by a group of Chinese researchers and scholars in the Zhangjiang Drug Valley of Shanghai in 2016. Stemirna Therapeutics is dedicated to developing the best mRNA drug platforms and pipeline.
DMed is a global contract research organization (CRO) based in China. Many of DMed‘s employees are industry elites from transnational pharmaceutical enterprises and experts from medical products administrations in China and the US. With years of experience in drug development, DMed provides customers with valuable insights and reliable operation management in all areas from plan design to filing strategy, from operation execution to quality assurance, and offers high-quality and comprehensive clinical services to pharmaceutical companies.
Founded in 2015 and based in Seoul, South Korea, Eutilex Co., Ltd. (Stock Code: 263050.KOSDAQ) is a biotechnology company focused on the research and development of innovative T cell receptor (TCR) T cell, chimeric antigen receptor (CAR) T cell, and immunomodulatory antibody therapeutics for cancer and autoimmune diseases. Eutilex is developing preclinical and clinical-stage immunotherapeutics using its three in-house platform technologies.
Longyao biotechnology co,. was founded in 2013, committed to developing cell therapy technology, technology transformation, regulatory filing and submission. The company is a national high-tech enterprise, focusing on the R&D of immunotherapies, targeting at blood tumor, solid tumor, etc.
Merck is a leading global technology company focused on three major areas: 1) Medicine and health: providing prescription drugs for the treatment of cancer, multiple sclerosis and infertility, cardiovascular diseases and metabolic diseases; 2) Life sciences: provide innovative tools and laboratory supplies; 3) High-performance materials: organic light-emitting diodes, paints and cosmetic functional pigments, solar panel functional materials, etc.
Genopis, Inc. was established in August 2018. The facility serves as the site for cGMP manufacturing operations, with currently capabilities suited for microbial-based products and expandable for future mammalian-based products. Genopis specializes in plasmid DNA based technology.
Legend Biotech Co., Ltd. was established on November 17, 2014. Now, Legend has built end-to-end capabilities including one of the world’s largest internal discovery research engines in cell therapy and a global manufacturing network for robust and cost-effective product supply. With operations in the US, Europe and China, Legend is uniquely positioned to enable accelerated global clinical development and commercialization of innovative cell therapies.
Kang Litai Pharmaceutical Co., Ltd. was established in 2011. Since its establishment, it has been committed to the research and development of KLT-1101 in the field of comprehensive recovery of blood and tumor immunotherapy. KLT-1101 is a recombinant human protein cytokine, which has a positive response in the recovery of whole blood, inhibiting the growth of tumor cells and improving the immunity of patients.
REMD biotherapeutics is located in Camerillo, California, and Beijing, China (the "Corson Virtue"), dedicated to the development of innovative protein drugs to treat metabolic abnormalities and other serious diseases. The main product is REMD-477, which is a fully human antibody against glucagon, and is currently undergoing clinical trials for the treatment of diabetes. At the same time, a variety of therapeutic antibodies against G-protein coupled have been developed.
ABL Bio was established in South Korea in 2016 and plays a leading role in the development of therapeutic drugs for the treatment of immune cancer and degenerative brain diseases. Since its establishment, the company has successfully completed nearly 100 million US dollars of financing and is currently preparing for the public listing of the Korean Stock Exchange (KOSDAQ).
Selecxine was established in Pohang, South Korea in December 2018.Selecxine is a biological startup that uses platform technology to develop monoclonal antibodies. Based on the understanding of cancer immunology and protein structure information, Selecxine develops antibodies that bind to specific epitopes of targeted proteins to adjust and amplify the signals emitted by bifunctional biomolecules such as cytokines and cytokine receptors.
Genome & Company is a clinical stage biotechnology company headquartered in Korea, focusing on the discovery and development of a new wave of innovative immuno-oncology therapies through different models of microbiome, new targeted immune checkpoint inhibitors and fusion proteins to meet the unmet needs of cancer patients.
SAFE Pharmaceutical was established in 2016, based on national level drug research and development units such as the Institute of Drug Innovation of the Chinese Academy of Sciences and the former National Beijing Drug Safety Evaluation and Research Center, etc. SAFE pharmaceutical is committed to become a world-class one-stop medical CRO service company and has following units/divisions: pharmaceutical development consultation, formulation and pre-formulation development, efficacy, disease animal models, pharmacokinetics, toxicology and safety evaluation, bioanalysis, bio-equivalency, clinical phaseⅠ-III and pharmacovigilance, etc.
OmniAb is a three-species transgenic-animal platform consisting of five different technologies used for producing mono- and bispecific human therapeutic antibodies. All five types of OmniAb therapeutic human antibody platform, OmniRat, OmniFlic, OmniMouse, OmniChicken and OmniClic, use patented technology, have broad freedom to operate, produce highly diversified, fully human antibody repertoires optimized in vivo for immunogenicity, manufacturability, and therapeutic efficacy, and deliver fully human antibodies with high affinity, specificity, expression, solubility and stability - Naturally Optimized Human Antibodies®.
CHONGQING CAMAB BIOTECH LTD is a High-Tech company，which has created the therapeutic antibody discovery platforms (CAMouseHG and CAMouseMG) with authentic human immunoglobulin loci including both human heavy and light chains and a nanobody discovery platform (CAMouseH) with human heavy chain-dCH1 locus; these platforms could generate high affinity, druggable, conventional human antibodies and nanobodies (heavy-chain only) upon antigen immunizations.